PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

Thank you for your treatise on penny stock fraud. The problem is in trying to connect those issues seen in many penny stocks to this particular situation with ROTH without any evidence or information aside from statements like a sampling below:
Sucanon is a dud/fraud: Not according to published studies including double blind placebo controlled study where Sucanon outperformed Glyburide without the weight gain. It is of further note that this particular study was performed when Biotech holdings owned the rights to Sucanon and none of the people that you have taken issue with were involved with Sucanon or the company aside from Luis Lopez, then head of operations in Mexico City (who you have stated does not run the company now). Listed on otcmarkets.com as CEO though.
"Shell owners run the company": See above
"Hundreds of millions of shares at zero cost basis" and "little to no sales": Share sales, price/amount/date in private transactions as well as revenues are reported quarterly and annually on an unaudited basis at otcmarkets.com for any to examine. I can find no basis for the claim of shares at zero cost basis. Regarding sales, note the recent reports of 2 orders for Sucanon of $80k each within the month of Sep 2015.
"Sucanon and ROTH are scams": Sucanon works based on the studies, and ROTH has real sales in real stores, which can be verified by a visit to Farmacias Similares among other outlets where Sucanon is sold over the counter in Mexico. The scams described in your treatise generally involve a company with no sales and no product with no verifiable results. IF that is the case then a pump and dump would be the only alternative. The thing is there is no pump and dump here. No promoter or hype. Just publically verifiable results of Sucanon efficacy and the sales, which though improving, have been less than spectacular given previously ineffective marketing. That appears to be changing due to better marketing focus.
Ultimately, IMO, the success of ROTH will hinge on the ability to communicate the results of Sucanons efficacy which is spectacular given the studies. IMO it will likely become an initial treatment for type 2 and prediabetics based on efficacy and weight/fat loss in contrast to the significant side effects observed in the current first line drugs like metformin, sulfonylureas etc.